Last Price | 4.71 | Max Price | 6.58 |
Min Price | 2.08 | 1 Year return | -24.28 |
Avg. Target | 11.80 | Expected Return | 150.53 % |
Sector | Health Care | Subsector | Health Care Eq. & Services |
Sell | 0 | Rating | |
Hold | 0 | Concensus | |
Buy | 3 |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 0 | 2,019,627 | 0.00 % |
2020 | 0 | 2,170,562 | 0.00 % |
2021 | 0 | 2,404,921 | 0.00 % |
2022 | 0 | 2,645,840 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
Date Label | Bank Label | Stock Label | Advice Label | Price Label | Diff Label |
---|---|---|---|---|---|
April 08, 2024 | Stifel | ONWARD | Buy | 12.00 | 60.75 % |
March 22, 2024 | KBC Securities | ONWARD | Buy | 9.30 | 49.35 % |
March 11, 2024 | DeGroof Petercam | ONWARD | Buy | 14.10 | 66.60 % |
February 09, 2024 | KBC Securities | ONWARD | Buy | 10.00 | 52.90 % |
March 28, 2023 | DeGroof Petercam | ONWARD | Buy | 14.10 | 66.60 % |
November 08, 2022 | DeGroof Petercam | ONWARD | Buy | 14.10 | 77.52 % |
September 13, 2022 | DeGroof Petercam | ONWARD | Buy | 14.50 | 70.90 % |
September 13, 2022 | Kepler Capital Markets | ONWARD | Buy | 14.00 | 69.86 % |
April 26, 2022 | DeGroof Petercam | ONWARD | Buy | 14.50 | 66.62 % |
March 23, 2022 | DeGroof Petercam | ONWARD | Buy | 14.90 | 70.47 % |
KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share
ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)
ONWARD® TO PARTICIPATE IN BASEL HEALTHTECH CONFERENCE 2024
Bryan Garnier Initiates Coverage of ONWARD with a Buy Rating and Target Price of EUR 17.00
No Records Found
No Records Found
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
0
|
0
|
0
|
0
|
0
|
|
Costs |
0
|
0
|
0
|
10
|
13
|
20
|
Profit |
0
|
0
|
0
|
-10
|
-13
|
-20
|
Margin of profit |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
ROI |
0.0
|
0.0
|
0.0
|
96.49
|
90.35
|
62.34
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
0
|
0
|
0
|
-10
|
-15
|
-32
|
Debt |
0
|
0
|
0
|
20
|
38
|
46
|
Total assets |
0
|
0
|
0
|
10
|
23
|
14
|
Solvency |
0.0
|
0.0
|
0.0
|
-107.43
|
-63.90
|
-226.22
|
Cash |
0
|
0
|
0
|
9
|
15
|
6
|
Cashflow |
0
|
0
|
0
|
-7
|
-10
|
-13
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.0
|
0.0
|
0.0
|
-0.36
|
-0.26
|
-0.28
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
0.0
|
0.0
|
0.0
|
0.0
|
4.71
|
Eps |
0.0
|
0.0
|
-0.33
|
-0.45
|
-0.67
|
Price/earnings-ratio |
0.0
|
0.0
|
0.0
|
0.0
|
-7.03
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
0.0
|
0.0
|
-0.34
|
-0.50
|
-1.08
|
Market to book |
0.0
|
0.0
|
0.0
|
0.0
|
-0.23
|
Cashflow per stock |
0.0
|
0.0
|
-0.24
|
-0.33
|
-0.43
|
Stocks |
0
|
0
|
30
|
30
|
30
|
Market Cap |
0.00
|
0.00
|
0.00
|
0.00
|
140.37
|
Date
|
Price
|
---|---|
21 May 2024
|
4.71
|
15 May 2024
|
4.71
|
10 May 2024
|
4.71
|
07 May 2024
|
4.71
|
01 May 2024
|
4.76
|
22 Apr 2024
|
5.30
|
18 Apr 2024
|
5.30
|
17 Apr 2024
|
5.30
|
09 Apr 2024
|
6.02
|
05 Apr 2024
|
4.88
|
03 Apr 2024
|
5.02
|
30 Mar 2024
|
4.78
|
22 Mar 2024
|
4.71
|
18 Mar 2024
|
6.14
|
15 Mar 2024
|
5.42
|
12 Mar 2024
|
5.88
|
11 Mar 2024
|
4.84
|
09 Mar 2024
|
4.84
|
07 Mar 2024
|
4.90
|
01 Mar 2024
|
4.71
|
29 Feb 2024
|
4.40
|
27 Feb 2024
|
5.38
|
22 Feb 2024
|
5.40
|
21 Feb 2024
|
5.64
|
20 Feb 2024
|
5.84
|
15 Feb 2024
|
5.78
|
14 Feb 2024
|
6.20
|
13 Feb 2024
|
6.58
|
09 Feb 2024
|
3.83
|
08 Feb 2024
|
3.83
|